Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked hard but unsuccessfully to develop an one-time therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last several shares. My 1st CytoDyn post, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set out the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire employment interview that I came away with a poor opinion of the company.

Irony of irony, my bad viewpoint of the company has grown steadily, although the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the therapy and avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the technology and connected intellectual property from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) as well as the very first new drug program endorsement ($5 million), and even royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and multiple indications, it’s this single remedy as well as a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy in dozens of indications.

Its opening banner on its website (below) shows an active company with diverse interests albeit focused on leronlimab, multiple illness types, multiple publications in addition to multiple delivering presentations.

Might all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really beginning of the interest of mine in this company. Judging with the multiples of a huge number of various responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a classic battleground, or perhaps some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *